DOCSLIB.ORG

27 August 2021 the Manager ASX Announcements Australian

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
27 August 2021 the Manager ASX Announcements Australian 27 August 2021 The Manager ASX Announcements Australian Securities Exchange Level 4 20 Bridge Street Sydney NSW 2000 Dear Sir / Madam ASX Appendix 4E (Preliminary Final Report) & Annual Report on Form 10-K Please find attached the following documents: • ASX Appendix 4E (Preliminary Final Report) for the 12-month period ended June 30, 2021 • Annual Report for the 12-month period ended June 30, 2021 (“Annual Report”) The Annual Report is prepared in accordance with U.S. Generally Accepted Accounting Principles (US GAAP) and is reported on Form 10-K. The Company will report its quarterly results for the three (3) month period ending September 30, 2021 on Form 10-Q and will hold a Company webcast to discuss those results in early November. Authorized by Dr Mike Perry Chief Executive Officer AVITA Medical, Inc. (ARBN 641 288 155) 28159 Avenue Stanford, Suite 220 Valencia, CA 91355 P +1(661) 367-9170 | f +1 (661) 367-9180 | avitamedical.com Registered Office: c/- Mertons Corporate Services Pty Limited Level 7, 330 Collins Street, Melbourne VIC 3000 Australia Appendix 4E Preliminary Final Report 30 June 2021 AVITA MEDICAL, INC. ARBN 641 288 155 Results for announcement to the market (In thousands, except net tangible asset backing per ordinary security) Movement June 2021 June 2020 Financial Results USD USD Sale of goods Up 105% 29,232 14,263 Other income Down 55% 2,072 4,612 Loss for the period attributable to owners of the parent Down 37% 26,583 42,030 Total comprehensive loss attributable to owners of the parent Down 37% 26,470 42,068 Record date for determining entitlements to dividends N/A – no dividends are proposed to be paid Net Tangible Asset Backing June 2021 June 2020 Net tangible asset backing per common stock outstanding $4.57 $3.3556 • Annual financial results: This report is based on the accompanying consolidated 2021 Financial Statements which have been audited by Grant Thornton LLP with the Report of Independent Registered Public Accounting Firm included in the 2021 Financial Statements. In this report, all references to “dollars” or “$” are to the currency of the United States. • Changes in control over entities: There were no entities over which AVITA Medical, Inc.’s (”Company”) control has been gained or lost during the fiscal year ended June 30, 2021. By way of background, the Company changed its corporate name from AVITA Therapeutics, Inc. to AVITA Medical, Inc., effective December 2, 2020 (United States time), after successfully filing a Certificate of Amendment of Certificate of Incorporation with the Secretary of State of Delaware. The Company’s change of name was registered with the Australian Securities and Investments Commission effective as from January 6, 2021. The Company’s common stock continues to trade on The NASDAQ Stock Exchange LLC under the symbol “RCEL” and its CHESS Depositary Interests continue to trade on the Australian Securities Exchange under the ticker symbol, “AVH”. • Details of dividends and dividend reinvestment plans: No dividends have been declared or proposed. • Details of associates or joint ventures: N/A • Set of accounting standards used in compiling the report: The audited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in U.S. dollars. • Details of audit disputes or audit qualification: None. Results of Operations: Total net revenue increased 105% to $29.2 million, compared to $14.3 million in the corresponding period in the prior year. RECELL® commercial revenues were $21.5 million, while RECELL revenues associated with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for Preparedness and Response (“BARDA”) were $7.7 million. Revenues associated with BARDA were attributable to the purchase of RECELL units for emergency preparedness by BARDA. RECELL commercial revenues increased by 50% or $7.2 million. Gross profit margin was 80% compared with 79% in the same period in the prior year, driven largely by lower shipping costs and increased production along with the extension of our shelf-life. BARDA income consisted of funding from BARDA, under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. Under the BARDA contract, income of $2.1 million was recognized during the year ended June 30, 2021, compared to income of $3.9 million for the year ended June 30, 2020. BARDA income declined as a result of the wind-down of certain activities associated with supporting the U.S. FDA approval of the RECELL System as well as the compassionate use, continued access programs and pivotal trials for the treatment of pediatric scald injuries. Total operating expenses decreased 10% or $6 million to $51.9 million, compared with $57.9 million incurred in the same period in the prior year. Sales and marketing expenses decreased $1 million or 7% to $14.7 million, compared to $15.7 million recognized in the same period in the prior year. The decrease in sales and marketing expenses is primarily due to fewer conferences, lower travel expenses due to COVID-19 related travel restrictions and higher costs incurred in the prior year associated with the product launch. General and administrative expenses decreased 32% or $10.6 million to $22.4 million compared with $33 million recognized in the same period in the prior year. The decrease was driven by higher share-based compensation expenses in the prior year associated with certain performance milestones being met along with higher costs related to the Avita group’s recomiciliation to the United States (which is discussed in further detail in the Company’s Form 10-K that is annexed to this Appendix 4E). Research and development expenses increased 61% or $5.6 million to $14.8 million, compared to $9.2 million recognized in the same period in the prior year. The increase was primarily attributed to the ramping up of clinical trials related activities for treatment of vitiligo as well as other research and development costs associated with furthering the Company’s pipeline. Net loss after tax decreased 37% or $15.4 million to $26.6 million, over the $42 million recognized in the same period in the prior year. The decrease in net loss was driven by higher revenue during the year, and lower operating expenses described above. Update on the Company’s Cash Position: The Company had cash, cash equivalents and restricted cash of $110.9 million at June 30, 2021 compared to $73.8 million at June 30, 2020. Net cash used in operating activities was $25.9 million and $22.7 million during the years ended June 30, 2021, and 2020, respectively. The increase during the 2021 fiscal year was primarily due to higher BARDA receivables attributable from the purchase of RECELL units by BARDA. Net cash used in investing activities was $1.2 million and $0.8 million during the years ended June 30, 2021, and 2020, respectively. Cash flows used for investing activities were primarily attributable to payments for the purchase of property and equipment. Net cash provided by financing activities was $64 million and $77.1 million for the years ended June 30, 2021, and 2020, respectively. The AVITA group completed a series of financing activities during the years ended June 30, 2021, and 2020 and received proceeds from the issuance of shares and exercise of options. Liquidity and Capital Resources: We aim to manage capital so that the Company continues as a going concern while also maintaining optimal returns to stockholders and benefits for other stakeholders. We also aim to maintain a capital structure that ensures the lowest cost of capital available to the Company. We regularly review the Company’s capital structure and seek to take advantage of available opportunities to improve outcomes for the Company and its stockholders. For the year ended June 30, 2021, there were no dividends paid and we have no plans to commence the payment of dividends. We have no committed plans to issue further shares on the market but will continue to assess market conditions and the Company’s cash flow requirements to ensure the Company is appropriately funded in order to continue its operations and pursue its various opportunities. 2 There is no significant external borrowing at the reporting date. Neither the Company nor any of the subsidiaries are subject to any externally imposed capital requirement. On March 1, 2021, the Company issued 3,214,250 shares of common stock at the offering price of $21.50 per share. The gross proceeds from the offering were approximately $69.1 million. The Company incurred $5.1 million in capital issuance expenses. Please refer to our audited consolidated financial statements with accompanying notes, which are attached hereto. Additional information Additional Appendix 4E disclosure requirements and commentary on these results are contained in the attached Form 10-K Annual Report for the period ended June 30, 2021. 3 Table of Contents e UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39059 AVITA MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 85-1021707 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 28159 Avenue Stanford Suite 220 Valencia, CA 91355 (Address of principal executive offices and Zip Code) Registrant’s telephone number, including area code: (661) 367-9170 Securities registered pursuant to Section 12(b) of the Act: Trading Name of each exchange Title of each class Symbol on which registered Common Stock, par value $0.0001 per share RCEL The NASDAQ Stock Market LLC Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Load more

Recommended publications
  • The Covid-19 Pandemic and Gender Inequality on the Labour Market: a Systematic Review and Future Directions
    THE COVID-19 PANDEMIC AND GENDER INEQUALITY ON THE LABOUR MARKET: A SYSTEMATIC REVIEW AND FUTURE DIRECTIONS BY DEBORA GOTTARDELLO AND DENI MAZREKAJ* Please do not circulate without the permission of the authors. Abstract The COVID-19 pandemic has been universally disruptive. Drastic governmental measures have led to substantial changes on the labour market, with many workers being laid off or working from home. This article investigates whether the pandemic has differentially affected women and men on the labour market, systematically synthesising 37 quantitative and qualitative articles published in peer-reviewed journals in 2020 and 2021. The results did not conclusively indicate a gendered effect on employment and earnings. The evidence was highly mixed and depended on the outcome of study, the method, and the sample. On the other hand, the results suggest that the pandemic has disproportionately impacted the emotional, psychological, and social wellbeing of women over men. This resulted in a greater negative effect on women’s work performance, particularly for working mothers. *Debora Gottardello (corresponding author): Cranfield School of Management, Cranfield University, College Rd, Cranfield, Wharley End, MK43 0AL Bedford, United Kingdom (e-mail: [email protected]); Faculty of Economics and Business, Universitat Oberta de Catalunya, Av.Tibidabo, 39-43, 08035, Barcelona, Spain; Deni Mazrekaj: Department of Sociology, University of Oxford, Park End Street 42-43, OX1 1JD Oxford, United Kingdom (e-mail: [email protected]); Leuven Economics of Education Research (LEER), KU Leuven, Naamsestraat 69, 3000 Leuven, Belgium (e-mail: [email protected]); Deni Mazrekaj acknowledges funding by the European Research Council [grant number: 681546].
    [Show full text]
  • Dokumentum Címe
    Acta Zoologica Academiae Scientiarum Hungaricae 67(2), pp. 101–117, 2021 DOI: 10.17109/AZH.67.2.101.2021 NEW SPECIES OF APTEROBIROINA L. PAPP AND BENTROVATA RICHARDS (DIPTERA, SPHAEROCERIDAE) FROM AUSTRALIA László Papp†* H-2200 Monor, Németh Á. u. 3, Hungary and Hungarian Natural History Museum, H-1088 Budapest, Baross u. 13, Hungary Apterobiroina flavipes sp. n., A. truncata sp. n., Bentrovata flavithorax sp. n., B. minor sp. n., B. nigrithorax sp. n. are described from Australia and compared to their type species Apterobi- roina australis L. Papp, 1979 as well as to Bentrovata regalis Richards, 1973. All these species are wingless, and only A. australis and A. flavipes have halteres. Keys are given for their identifications. With 53 original figures on seven tables. Key words: Apterobiroina, Bentrovata, new species, wingless species, Australia, taxonomy. INTRODUCTION In the course of a collection revision of the Diptera Collection of the De- partment of Zoology, Hungarian Natural History Museum, Budapest, there emerged again the necessity of the descriptions of some wingless specimens, which were selected and separated to species but left undescribed ten years ago. Reduction of wings and even that of halteres is a widespread phenom- enon among the species of Sphaeroceridae. One can find wingless or reduced- winged species in all the four subfamilies, most of them in the subfamily Li- mosininae. Their best expert, Prof. O. W. Richards, published 25 papers and book chapters on them between 1931 and 1980, e.g. Richards (1965). The highest proportion of the wingless and reduced-winged species and genera are living in the Afrotropical Region (see Papp & Roháček 2021).
    [Show full text]
  • Annual Report 2021
    PSC Insurance Group Limited ANNUAL REPORT 2021 PSC Insurance Group Limited & Controlled Entities ACN 147 812 164 Level 4, 96 Wellington Parade East Melbourne VIC 3002 www.pscinsurancegroup.com.au 2 PSC INSURANCE GROUP LIMITED AND CONTROLLED ENTITIES CONTENTS Chairman’s Letter ............................................................................................................................................... 1 Managing Director’s Report ...........................................................................................................................2 Environmental and Social Statement Corporate Governance Statement ......................................6 Directors’ Report ..............................................................................................................................................15 Auditors Independence Declaration......................................................................................................... 27 Financial Statements ...................................................................................................................................... 28 Notes To The Financial Statements .......................................................................................................... 32 Directors’ Declaration .................................................................................................................................... 88 Independent Auditor’s Report ...................................................................................................................
    [Show full text]
  • June 2021 Quarterly Update Painchek Adult App Achieves 60
    ASX ANNOUNCEMENT 29 July 2021 June 2021 Quarterly Update PainChek Adult App achieves 60% share of Australian Residential Aged Care market, new Infant App receives regulatory clearance for commercialisation in multiple markets HIGHLIGHTS Increases in all sales and project related KPI’s across the business for the quarter: • Residential Aged Care growth: 1,569 Residential Aged Care (RAC) facilities and 129,189 approved beds are now under annual PainChek® licence as at 30 June 2021, representing 117% and 110% growth respectively over the previous year and 60% domestic market share. • Annualised Recurring Revenue (ARR): Australian clients will be transitioning from government funding agreement to PainChek standard contracts after their first 12 months. Projected ARR from current customers (normalised post government trial) increases 109% for the year and 60% for the quarter to $5.57M. • PainChek utility: More than 479,000 PainChek clinical assessments have been conducted in aged care as of 30 June 2021, an increase of 253% over the previous year reflecting strong clinical utility and continued implementation progress within Australian RAC Facilities. • PainChek Universal Solution: Product received CE Mark and TGA clearance during Q1 2021 and has commenced roll out as a system upgrade to all existing clients. The Universal App has been shown to broaden existing market potential, accelerate new take up and support ongoing retention. • PainChek Infants: PainChek Infant received multiple market regulatory clearances including Australian TGA and CE Mark (Europe) during Q2 2021. Clinical trial data was peer reviewed and accepted for publication in the Lancet Digital Health journal. Company now well positioned to commercialize the first sector of the large Children’s markets in Australia and overseas.
    [Show full text]
  • 6G Fundamentals: Vision & Enabling Technologies
    6G Fundamentals: Vision & Enabling Technologies Towards Trustworthy Solutions & Resilient Systems Author: David Soldani Published by 6GWorld, 15 June 2021 Link:https://www.6gworld.com/latest-research/6g-fundamentals-vision-and-enabling-technologies/ Reference number: 6GW02 Page | 1 6G Gains Momentum While the next generation of mobile connectivity still lies roughly a decade ahead, the number of 6G initiatives ongoing globally, and corresponding investments provide an intriguing prospect for the future. Public and private sectors have already started investing in research and innovation (R&I) actions to tackle requirements that 6G will probably demand when it reaches commercial reality around 2030 (Castro, 2021, 5G Americas, 2021b). These include use cases promised in 5G networks but not yet realised, and more advanced scenarios that are emerging in the context of next generation/6G networks such as Terahertz frequencies, holoportation, tactile/haptic communications, ubiquitous services (land, air, space, sea), medical/health services, government/national security, imaging and sensing, first responder/emergency services, cyber-physical systems/manufacturing, and transportation services. Some examples of relevant use cases and corresponding technology requirements are shown in Figure 1 (5G Americas, 2021b). For more information and other usage scenarios towards 6G, the reader may refer to, e.g., (6G Flagship, 2021a, 6GIC Vision, 2021). Specific international efforts by leading nations in the wireless cellular industry and relevant Beyond 5G (B5G) and 6G initiatives and related investments are illustrated in Figure 2. In Europe, within the EU Horizon 2020 R&I framework programme, three recent joint projects focused on 6G development have been announced: Hexa-X, RISE-6G, and NEW-6G.
    [Show full text]
  • ASX Announcement Form 8K
    NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS ASX Announcement 28 June 2021 Form 8K Coronado Global Resources Inc. (ASX: CRN) advises that it has lodged the attached Form 8K with the U.S. Securities and Exchange Commission (SEC) in relation to the resignation of the Chief Legal Officer and Company Secretary. This announcement was authorised to be given to the ASX by the Board of Coronado Global Resources Inc. – Ends – For further information please contact: Investors Investors Media Andrew Mooney Matthew Sullivan Brett Clegg P: +61 458 666 639 P: +61 412 157 276 Citadel Magnus E: [email protected] E: [email protected] P: +61 487 436 985 Coronado Global Resources Inc. Level 33, Central Plaza One, 345 Queen Street ARBN: 628 199 468 Brisbane QLD 4000 T: +61 7 3031 7777 | F: +61 7 3229 7402 www.coronadoglobal.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 1 5(d) of the Securities Exchange Act of 1 934 Date of Report (Date of earliest event reported): June 24, 2021 Coronado Global Resources Inc. (Exact name of registrant as specified in its charter) Delaware 000-56044 83-1780608 (State or other jurisd iction of (Commission File Number) (IRS Employer Identification No.) incorporation) Level 33, Central Plaza One, 345 Queen Street Brisbane, Queensland, Australia 4000 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (61) 7 3031 7777 Not Applicable (Former name
    [Show full text]
  • The Role of ICT and Energy Consumption on Carbon Emissions: an Australian Evidence Using Cointegration Test and ARDL Long-Run and Short-Run Methodology
    International Journal of Energy Economics and Policy ISSN: 2146-4553 available at http: www.econjournals.com International Journal of Energy Economics and Policy, 2021, 11(5), 441-449. The Role of ICT and Energy Consumption on Carbon Emissions: An Australian Evidence Using Cointegration Test and ARDL Long-run and Short-run Methodology Avishek Khanal* School of Business, University of Southern Queensland, Australia. *Email: [email protected] Received: 22 April 2021 Accepted: 04 July 2021 DOI: https://doi.org/10.32479/ijeep.11419 ABSTRACT Information and communication technology (ICT) and energy consumption have substantially increased use over the last decade. It has become one of the essential aspects for improving the standard of life for many people. This study investigates the impact of internet use and energy consumption on the carbon emissions (CO2 emissions) using annual data from 1990 to 2019 in Australia. For this investigation, ADF and PP unit root tests were applied with the Zivot-Andrews structural break for the unit root test. The paper implements the ARDL cointegration test, JJ cointegration test, and Bayer-Hanck test to check the long-run relationship between carbon dioxide emissions (CO2), internet use, and energy consumption with GDP and total population. The cointegration test results show that there exists a long-run relationship between the variables. The long-run findings reveal a negative impact of ICT on the environment, whereas energy consumption has a positive and significant impact on the environment. According to the short-run dynamics results, both internet usage and energy consumption have a positive and statistically significant impact.
    [Show full text]
  • Game, Set, Match: Calling Time on Climate Inaction
    GAME, SET, MATCH: CALLING TIME ON CLIMATE INACTION CLIMATECOUNCIL.ORG.AU Thank you for Dr Martin Rice supporting the Head of Research Climate Council. Ella Weisbrot Researcher (Climate Solutions) The Climate Council is an independent, crowd-funded organisation providing quality information on climate change to the Australian public. Dr Simon Bradshaw Researcher (Climate Science & Impacts) Professor Will Steffen Councillor (Climate Science & Impacts) Published by the Climate Council of Australia Limited. ISBN: 978-1-922404-15-2 (print) 978-1-922404-14-5 (digital) © Climate Council of Australia Ltd 2021. Professor Lesley Hughes This work is copyright the Climate Council of Australia Ltd. All material Councillor (Climate Science & Impacts) contained in this work is copyright the Climate Council of Australia Ltd except where a third party source is indicated. Climate Council of Australia Ltd copyright material is licensed under the Creative Commons Attribution 3.0 Australia License. To view a copy of this license visit http://creativecommons.org.au. Professor Hilary Bambrick You are free to copy, communicate and adapt the Climate Council of Councillor (Health) Australia Ltd copyright material so long as you attribute the Climate Council of Australia Ltd and the authors in the following manner: Game, Set, Match: Calling time on climate inaction. Authors: Martin Rice, Ella Weisbrot, Simon Bradshaw, Will Steffen, Lesley Hughes, Hilary Bambrick, Kate Charlesworth, Nicki Hutley, and Lisa Upton. Dr Kate Charlesworth Councillor (Health) — Cover image:
    [Show full text]
  • Inquiry Into the Impact of the COVID‑19 Pandemic on the Tourism and Events Sectors
    PARLIAMENT OF VICTORIA LEGISLATIVE COUNCIL Economy and Infrastructure Committee Inquiry into the impact of the COVID‑19 pandemic on the tourism and events sectors Parliament of Victoria Legislative Council Economy and Infrastructure Committee Ordered to be published VICTORIAN GOVERNMENT PRINTER August 2021 PP No 254, Session 2018–2021 ISBN 978 1 922425 35 5 (print version), 978 1 922425 36 2 (PDF version) Committee membership CHAIR DEPUTY CHAIR Mr Enver Erdogan Mr Bernie Finn Mr Rodney Barton Southern Metropolitan Western Metropolitan Eastern Metropolitan Mr Mark Gepp Mrs Bev McArthur Mr Tim Quilty Mr Lee Tarlamis OAM Northern Victoria Western Victoria Northern Victoria South Eastern Metropolitan Participating members Dr Matthew Bach, Eastern Metropolitan Ms Melina Bath, Eastern Victoria Dr Catherine Cumming, Western Metropolitan Hon David Davis, Southern Metropolitan—substitute Member for Mrs McArthur for this Inquiry Mr David Limbrick, South Eastern Metropolitan Hon Wendy Lovell, Northern Victoria—substitute Member for Mr Finn for this Inquiry Mr Andy Meddick, Western Victoria Mr Craig Ondarchie, Northern Metropolitan Hon Gordon Rich-Phillips, South Eastern Metropolitan Ms Sheena Watt, Northern Metropolitan ii Legislative Council Economy and Infrastructure Committee About the Committee Functions The Legislative Council Economy and Infrastructure Committee’s functions are to inquire into and report on any proposal, matter or thing concerned with agriculture, commerce, infrastructure, industry, major projects, public sector finances, transport and education. As a Standing Committee, it may inquire into, hold public hearings, consider and report on any Bills or draft Bills, annual reports, estimates of expenditure or other documents laid before the Legislative Council in accordance with an Act, provided these are relevant to its functions.
    [Show full text]
  • (Medinfo) 2021 Sydney, Australia
    S Y D N E Y World Congress on Medical and Health Informatics (MedInfo) 2021 Sydney, Australia Submitted May 2017 CONFIDENTIAL This document and its contents are the intellectual property of the Health Informatics Society of Australia (HISA) and Business Events Sydney (BESydney). You must not share, copy or adapt this document, or any part of it, without prior written consent from HISA or BESydney. © HISA and BESydney 2017 2 Table of contents Letter of Invitation 3 Executive Summary 4 Part I – Society Profile and Capabilities 6 1. Goals and objectives in successfully bidding for MedInfo 2021 7 2. Profile of the bidding Society or Association 9 3. Proposed dates and location for MedInfo 13 4. National and regional support 16 5. Proposed composition of Local Organizing Committee 19 Part II – Requirements & Obligations 20 1. Financial obligations 21 2. Benefits to IMIA Institutional Members 21 3. Other requirements 22 Part III – Tentative Budget Proposal 24 Congress budget 25 Part IV – Bid Summary 29 Accompanying persons program 34 10 Must-dos in Sydney 36 Just outside Sydney 38 Appendices 40 Appendix 1: HISA financial statements 41 Appendix 2: ICC Sydney room schedule and floor plans 70 Appendix 3: Potential sponsors for MEDINFO 2021 73 Appendix 4: Letters of support 75 Appendix 5: Business Events Sydney Strategic Partners 84 Business Events Sydney Terms and Conditions 90 3 Letter of Invitation 15 May 2017 Dr. Hyeoun‐Ae Park President International Medical Informatics Association c/‐Health On the Net, Chemin du Petit‐Bel‐Air 2, CH‐1225 Chene‐Bourg Geneva, Switzerland Dear Dr Park, On behalf of the Health Informatics Society of Australia (HISA) and the Local Organising Committee (LOC), we are delighted to invite the World Congress on Medical and Health Informatics (MedInfo) to Sydney, Australia in 2021.
    [Show full text]
  • Annual Report 2021
    Annual Report 2021 2 13 2 Our next chapter /03 A strong sense of fulfillment 04/ Chair and Chief Executive Report /06 Board of Directors /10 Executive Team /12 The winds of change /14 Wider interest /24 Human energy /31 Think safety /38 Sharing our spaces /43 Sustaining value /50 Financial statements /63 Statutory information /120 Directory /133 1 2 OUR NEXT CHAPTER 5 The sale of Tilt Renewables, which is expected to be completed in August 2021, has allowed the market to confirm the value we have created through successfully pursuing our vision – to drive the transition to renewables through OUR NEXT everything we do. Since October 2016, our team has delivered three new wind power projects totalling 523MW. Those projects include the largest turbines installed in New Zealand as well as our largest asset at Dundonnell in Australia. We’ve also grown our pipeline of development options to more than 5GW. We are already a large part of the renewable transition in both countries and look CHAPTER forward to continuing in that role. We believe the change of owners will not alter the focus of the team, our approach to stakeholders or the way we act as a long term member of our host communities. All our people are leaning forward, finding ways to deal with complexity and continue to provide leading investment opportunities for our shareholders. 3 A STRONG SENSE OF FULFILMENT 133MW WAIPIPI EMISSIONS-FREE ENERGY PRODUCED - COMPLETED ON TIME - COMPLETED WITHIN BUDGET 1,840 GWH WITH WAIPIPI AND DUNDONNELL WIND FARMS CONTRIBUTING 40% OF FY21 TOTAL GENERATION
    [Show full text]
  • News Events/Webinars
    N o.5 2 , 6 A p r i l 2021 NEWS DO YOU HAVE PHOTOS OR VIDEO FOOTAGE FOR WORLD COMMUNICATIONS DAY 2021? The Australian Catholic Media Council, an advisory body to the Australian Catholic Bishops Conference, has proposed the development of a campaign drawing on the theme for World Communications Day 2021: Come and See, to be held 9 May 2021 in Australia. The Media Council is asking if you have high-quality photo and/or video content that has already been shot, that could be used for the Come and See campaign, which will show “the Church in action,” eg: Catholic education; hospitals; aged care; social services; ministry with Aboriginal and Torres Strait Islander Catholics; and parish and community engagement. The compilation and editing work will be overseen by the Bishops Conference’s Media and Communications Department. Please read more about the campaign and instructions on how to share photo or video content. If you can assist, please do so no later than Friday, 16 April 2021. CONVOCATIONS OF CATHOLICS The Australasian Catholic Coalition for Church Reform (ACCCR) is organising a series of three Convocations of Catholics, promoting Church renewal in the context of the Plenary Council and the signs of the times in Australia. The first will be on Sunday, 2 May 2021 with Joan Chittister OSB, by Zoom. CRA will circulate information about the Convocation with Joan Chittister when registrations are open. In the meantime, please see the ARCCCR appeal for sponsorship support and Convocation Information. EVENTS/WEBINARS WEBINAR SERIES FROM PONTIFICAL UNIVERSITY OF THE HOLY CROSS, ROME Title: Inspiring Trust – click here to find out more or download the brochure Date: April to May 2021 Format: 6 sessions: April 22 and 29; May 6, 13, 20 and 27 Time: 3:00pm - 5:00pm (time in Rome) click here for the full schedule Registration: Online registration Audience: Anyone responsible for communications in their religious institute.
    [Show full text]